Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 230

Similar articles for PubMed (Select 23352841)

1.

A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer.

Qu X, Randhawa G, Friedman C, O'Hara-Larrivee S, Kroeger K, Dumpit R, True L, Vakar-Lopez F, Porter C, Vessella R, Nelson P, Fang M.

Cancer Genet. 2013 Jan-Feb;206(1-2):1-11. doi: 10.1016/j.cancergen.2012.12.004. Epub 2013 Jan 24.

2.

ERG protein expression over time: from diagnostic biopsies to radical prostatectomy specimens in clinically localised prostate cancer.

Berg KD, Brasso K, Thomsen FB, Røder MA, Holten-Rossing H, Toft BG, Iversen P, Vainer B.

J Clin Pathol. 2015 Jun 9. pii: jclinpath-2015-202894. doi: 10.1136/jclinpath-2015-202894. [Epub ahead of print]

PMID:
26060265
3.

The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.

Berg KD, Røder MA, Thomsen FB, Vainer B, Gerds TA, Brasso K, Iversen P.

Prostate. 2015 Jun 5. doi: 10.1002/pros.23026. [Epub ahead of print]

PMID:
26053696
4.

Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate Tumors.

Dubovenko A, Serebryiskaya T, Nikolsky Y, Nikolskaya T, Perlina A, JeBailey L, Bureeva S, Katta S, Srivastava S, Dobi A, Khasanova T.

J Cancer. 2015 Apr 1;6(6):490-501. doi: 10.7150/jca.8213. eCollection 2015.

5.

NKX3.1 Suppresses TMPRSS2-ERG Gene Rearrangement and Mediates Repair of Androgen Receptor-Induced DNA Damage.

Bowen C, Zheng T, Gelmann EP.

Cancer Res. 2015 Jul 1;75(13):2686-2698. Epub 2015 May 14.

PMID:
25977336
6.

Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.

Zeng W, Sun H, Meng F, Liu Z, Xiong J, Zhou S, Li F, Hu J, Hu Z, Liu Z.

Int J Clin Exp Pathol. 2015 Feb 1;8(2):1878-88. eCollection 2015.

7.

Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer.

Urbinati G, Ali HM, Rousseau Q, Chapuis H, Desmaële D, Couvreur P, Massaad-Massade L.

PLoS One. 2015 May 1;10(5):e0125277. doi: 10.1371/journal.pone.0125277. eCollection 2015.

8.

Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods.

He J, Schepmoes AA, Shi T, Wu C, Fillmore TL, Gao Y, Smith RD, Qian WJ, Rodland KD, Liu T, Camp DG 2nd, Rastogi A, Tan SH, Yan W, Mohamed AA, Huang W, Banerjee S, Kagan J, Srivastava S, McLeod DG, Srivastava S, Petrovics G, Dobi A, Srinivasan A.

J Transl Med. 2015 Feb 12;13:54. doi: 10.1186/s12967-015-0418-z.

9.

Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss of PTEN expression and overexpression of EGFR.

Simper NB, Jones CL, MacLennan GT, Montironi R, Williamson SR, Osunkoya AO, Wang M, Zhang S, Grignon DJ, Eble JN, Tran T, Wang L, Baldrige LA, Cheng L.

Hum Pathol. 2015 Jun;46(6):805-12. doi: 10.1016/j.humpath.2015.02.004. Epub 2015 Feb 26.

PMID:
25870120
10.

Obesity and Prostate Cancer Risk According to Tumor TMPRSS2:ERG Gene Fusion Status.

Egbers L, Luedeke M, Rinckleb A, Kolb S, Wright JL, Maier C, Neuhouser ML, Stanford JL.

Am J Epidemiol. 2015 May 1;181(9):706-13. doi: 10.1093/aje/kwu344. Epub 2015 Apr 7.

PMID:
25852077
11.

Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India.

Ateeq B, Kunju LP, Carskadon SL, Pandey SK, Singh G, Pradeep I, Tandon V, Singhai A, Goel A, Amit S, Agarwal A, Dinda AK, Seth A, Tsodikov A, Chinnaiyan AM, Palanisamy N.

Prostate. 2015 Jul;75(10):1051-62. doi: 10.1002/pros.22989. Epub 2015 Mar 23.

PMID:
25809148
12.

Prostate cancer: ERG fusion and AKR1C3 form AR signalling feed-forward loop.

Fenner A.

Nat Rev Urol. 2015 May;12(5):239. doi: 10.1038/nrurol.2015.61. Epub 2015 Mar 24. No abstract available.

PMID:
25800398
13.

ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells.

Powell K, Semaan L, Conley-LaComb MK, Asangani I, Wu YM, Ginsburg KB, Williams J, Squire JA, Maddipati KR, Cher ML, Chinni SR.

Clin Cancer Res. 2015 Jun 1;21(11):2569-79. doi: 10.1158/1078-0432.CCR-14-2352. Epub 2015 Mar 9.

PMID:
25754347
14.

TMPRSS2, a novel membrane-anchored mediator in cancer pain.

Lam DK, Dang D, Flynn AN, Hardt M, Schmidt BL.

Pain. 2015 May;156(5):923-30. doi: 10.1097/j.pain.0000000000000130.

PMID:
25734995
15.

The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer.

Graff RE, Pettersson A, Lis RT, DuPre N, Jordahl KM, Nuttall E, Rider JR, Fiorentino M, Sesso HD, Kenfield SA, Loda M, Giovannucci EL, Rosner B, Nguyen PL, Sweeney CJ, Mucci LA; Transdisciplinary Prostate Cancer Partnership ToPCaP.

Prostate. 2015 Jun;75(9):897-906. doi: 10.1002/pros.22973. Epub 2015 Mar 1.

PMID:
25728532
16.

Prevalence of chromosomal rearrangements involving non-ETS genes in prostate cancer.

Kluth M, Galal R, Krohn A, Weischenfeldt J, Tsourlakis C, Paustian L, Ahrary R, Ahmed M, Scherzai S, Meyer A, Sirma H, Korbel J, Sauter G, Schlomm T, Simon R, Minner S.

Int J Oncol. 2015 Apr;46(4):1637-42. doi: 10.3892/ijo.2015.2855. Epub 2015 Jan 27.

PMID:
25625310
17.

Clinical significance of ERG rearrangement subtype and its association with increased p53 expression in Japanese and German prostate cancer.

Nishijima J, Hara T, Ikemoto K, Oga A, Kobayashi K, Kawai Y, Matsumoto H, Nagao K, Sasaki K, Gkoleizakis V, Fichtner J, Matsuyama H.

Neoplasma. 2015;62(2):278-87. doi: 10.4149/neo_2015_033.

PMID:
25591593
18.

Correction: Androgen Receptor CAG Repeat Polymorphism and Risk of TMPRSS2:ERG-Positive Prostate Cancer.

[No authors listed]

Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):318. doi: 10.1158/1055-9965.EPI-14-1205. No abstract available.

PMID:
25587112
19.

Prognostic and predictive molecular biological markers in prostate cancer - significance of expression of genes PCA3 and TMPRSS2.

Soumarova R, Boday A, Krhutova V, Janotova A, Dvorakova M, Jaluvkova E, Stursa M, Perkova H.

Neoplasma. 2015;62(1):114-8.

PMID:
25563374
20.

TMPRSS2-ERG gene fusion in prostate cancer.

Burdova A, Bouchal J, Tavandzis S, Kolar Z.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014 Dec;158(4):502-10. doi: 10.5507/bp.2014.065. Epub 2014 Dec 5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk